

# Somatic Symptom Disorder

STUART L. KURLANSIK, PhD, and MARIO S. MAFFEI, MD  
*Virtua Family Medicine Residency Program, Voorhees, New Jersey*

With the release of the *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed., the diagnostic category previously known as somatoform disorders is now called somatic symptom and related disorders. The revisions were intended to increase their relevance in the primary care setting. The main feature of this disorder is a patient's concern with physical symptoms that he or she attributes to a nonpsychiatric disease. Primary care physicians often treat patients who manifest symptoms for which there are no biologic cause, and patients with somatic symptom disorder may be subjected to unnecessary testing and procedures. As a result, appropriate diagnosis is essential. Screening instruments are useful in determining the presence of somatic symptom disorder. It is important for the primary care physician to schedule regular appointments, establish a strong therapeutic alliance, acknowledge and legitimize the patient's symptoms, and limit diagnostic testing or referrals to subspecialists. Proven treatments include cognitive behavior therapy, mindfulness-based therapy, and pharmacotherapy. The use of selective serotonin reuptake inhibitors or tricyclic antidepressants has been effective in alleviating symptoms. Referral to a mental health professional may be necessary when treatment by the primary care physician is ineffective. (*Am Fam Physician*. 2015;93(1):49-54. Copyright © 2015 American Academy of Family Physicians.)

**CME** This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz Questions on page 14.

Author disclosure: No relevant financial affiliations.

► **Patient information:** A handout on this topic is available at <http://familydoctor.org/familydoctor/en/diseases-conditions/somatoform-disorders/symptoms.html>.

Somatization is said to be present when psychological or emotional distress is manifested in the form of physical symptoms that are otherwise medically unexplained.<sup>1</sup> Patients with multiple persistent physical symptoms that seem to have no apparent biologic basis are common in patients presenting to primary care.<sup>2</sup>

In the *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed., (DSM-5), the nomenclature for the diagnostic category previously known as somatoform disorders was changed to somatic symptom and related disorders.<sup>3</sup> The purpose of this change was to better define these disorders to make them more relevant to the primary care setting.

Somatic symptom disorder may be no less debilitating than physical disorders.<sup>4</sup> Patients experiencing somatization whose physicians incorrectly think they may have a biologic disorder can experience harm from unnecessary testing and treatment.<sup>5</sup> Some physicians find patients with somatic symptom disorder frustrating, and may describe them in derogatory terms. They may consider physical disorders genuine, while essentially accusing somaticizing patients of manufacturing their symptoms.<sup>6</sup>

This article provides practical suggestions for improving the care of these patients.

## Epidemiology

The prevalence of somatic symptom disorder in the general population is an estimated 5% to 7%,<sup>3</sup> making this one of the most common categories of patient concerns in the primary care setting.<sup>7</sup> An estimated 20% to 25% of patients who present with acute somatic symptoms go on to develop a chronic somatic illness.<sup>8</sup> These disorders can begin in childhood, adolescence, or adulthood.<sup>4,9</sup> Females tend to present with somatic symptom disorder more often than males, with an estimated female-to-male ratio of 10:1.<sup>9</sup>

## Etiology

Somatic symptoms may result from a heightened awareness of certain bodily sensations, combined with a tendency to interpret these sensations as indicative of a medical illness.<sup>9</sup> The etiology of somatic symptom disorder is unclear. However, studies have determined that risk factors for chronic and severe somatic symptoms include childhood neglect, sexual abuse, chaotic lifestyle, and a history of alcohol and substance abuse.

In addition, somatic symptom disorder has been associated with personality disorders.<sup>8</sup>

Psychosocial stressors and culture affect how patients present to the physician. For example, studies in primary care settings found significantly higher rates of unemployment and impaired occupational functioning in somaticizing patients compared with nonsomaticizing patients (29% vs. 15%, and 55% vs. 14%, respectively).<sup>4</sup> Patients may also present with physical symptoms when psychiatric symptoms are stigmatized, as in some cultures.<sup>10</sup>

### Diagnosis

Somatic symptom disorder presents a problem for both the physician and patient because it puts patients at risk of unnecessary testing and treatment.<sup>8,9,11</sup> The main feature of these disorders is a concern with physical symptoms that are attributed to a

nonpsychiatric disease.<sup>12</sup> This concern can manifest as one or more somatic symptoms that result in excessive thoughts, feelings, or behaviors related to those symptoms and that are distressing or result in significant disruption of daily life. One of the following criteria must also be present: significant thoughts about the seriousness of the symptoms; a high level of anxiety about the symptoms; or excessive energy spent with regard to symptomatic concern. Although somatic symptoms need not be continuously present, they must be persistent (present for more than six months). Two specifiers of this condition in the DSM-5 are “with predominant pain” and “persistent.” These disorders can be mild, moderate, or severe (*Table 1*).<sup>3</sup> Characteristics of the subclasses of somatic symptom disorder are described in *Table 2*.<sup>3</sup>

### Differential Diagnosis

The following diagnoses should be considered in patients with suspected somatic symptom disorder because the symptoms may be indicative of other mental health disorders: depression, panic disorder, generalized anxiety disorder, substance use disorder, syndromes of unclear etiology (e.g., nonmalignant pain syndrome, chronic fatigue syndrome), and nonpsychiatric medical conditions.<sup>12</sup>

### Screening

Although the Patient Health Questionnaire-15 (*eTable A*) is perhaps the most commonly used screening instrument to detect somatization symptoms in the general population,<sup>13</sup> the more recently developed Somatic Symptom Scale-8 (*Table 3*<sup>14</sup>) shows promise in measuring somatic symptom burden. A study to determine the reliability and validity of this newer tool concluded that it is a reliable and valid self-report measure of somatic symptom burden, and that cutoff scores identify persons with low, medium, high, and very high somatic symptom burden.<sup>15</sup> This instrument was validated on a representative random sample, including 2,510 persons 14 years and older, with overall good reliability. Because of overlap with symptoms of depression and anxiety,

**Table 1. Somatic Symptom Disorder**

#### Diagnostic criteria:

- A. One or more somatic symptoms that are distressing or result in significant disruption of daily life.
- B. Excessive thoughts, feelings, or behaviors related to the somatic symptoms or associated health concerns as manifested by at least one of the following:
  1. Disproportionate and persistent thoughts about the seriousness of one's symptoms.
  2. Persistently high level of anxiety about health or symptoms.
  3. Excessive time and energy devoted to these symptoms or health concerns.
- C. Although any one somatic symptom may not be continuously present, the state of being symptomatic is persistent (typically more than 6 months).

#### Specify if:

With **predominant pain** (previously pain disorder): This specifier is for individuals whose somatic symptoms predominantly involve pain.

#### Specify if:

**Persistent:** A persistent course is characterized by severe symptoms, marked impairment, and long duration (more than 6 months).

#### Specify current severity:

**Mild:** Only one of the symptoms specified in Criterion B is fulfilled.

**Moderate:** Two or more of the symptoms specified in Criterion B are fulfilled.

**Severe:** Two or more of the symptoms specified in Criterion B are fulfilled, plus there are multiple somatic complaints (or one very severe somatic symptom).

*Reprinted with permission from the American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013:311.*

**Table 2. Subsets of Somatic Symptom Disorder**

<i>Subset</i>	<i>Description</i>
Conversion disorder	One or more symptoms of altered voluntary motor or sensory function inconsistent with a known condition
Factitious disorder	Falsification of physical or psychological symptoms, or induced injury or disease; can be with regard to self or imposed on others, although not for personal gain (as with malingering)
Illness anxiety disorder	Preoccupation with getting or having a serious medical disorder; the two types include care-seeking and care-avoidant; previously included in hypochondriasis
Psychological factors affecting other medical conditions	A medical condition must exist and psychological factors must negatively affect the condition
Other specified somatic symptom and related disorders	Symptoms consistent with somatic symptom disorder are present, but do not meet full criteria for any of the above disorders
Unspecified somatic symptom and related disorders	Symptoms consistent with somatic symptom disorder are present, but do not meet criteria for any of the above disorders; should be used only when there is insufficient information to make a more specific diagnosis

*Information from reference 3.*

it is recommended that clinicians assess for these comorbidities as well.<sup>14</sup> It should be emphasized, however, that although screening instruments are useful as a first step in the diagnostic process, the DSM-5 criteria still must be met to diagnose somatic symptom disorders.

## Management

The management of somatic symptom disorders requires a multifaceted approach tailored to the individual patient. To choose the correct treatment plan, primary care clinicians should keep in mind psychological, social, and cultural factors that influence somatic symptoms.

General treatment tenets for the primary care clinician include scheduling regular, short-interval visits to avoid the need for symptoms to get an appointment; establishing a collaborative, therapeutic alliance with the patient; acknowledging and legitimizing symptoms once the patient has been evaluated for other medical and psychiatric diseases; limiting diagnostic testing; reassuring the patient that serious medical diseases have been ruled out; educating patients about

coping with physical symptoms; setting a treatment goal of functional improvement rather than cure; and appropriately referring patients to subspecialists and mental health professionals.<sup>16</sup> The CARE MD (consultation/cognitive behavior therapy, assessment, regular visits, empathy, medical/psychiatric interface, do no harm) treatment approach was developed to help primary care clinicians work more effectively with patients who have somatic symptom disorder (*Table 4*).<sup>17</sup> Proven therapies provided by mental health care professionals include cognitive behavior therapy and mindfulness-based therapy (*Table 5*).<sup>18-27</sup>

## PHARMACOTHERAPY

Medications used to treat somatic symptom disorder include antidepressants, antiepileptics, antipsychotics, and natural products. The effectiveness of many of these treatments has limited support.

Systematic reviews of controlled trials support the use of antidepressants for the treatment of somatic symptom disorder. In a meta-analysis of 94 trials, antidepressants provided substantial benefit, with a

## Somatic Symptom Disorder

number needed to treat of three.<sup>25</sup> Tricyclic antidepressants had notable success and were associated with a greater likelihood of effectiveness than selective serotonin reuptake inhibitors. Amitriptyline was the most studied tricyclic, and provided benefits for at least one of the following outcomes: pain, morning stiffness, global improvement, sleep, fatigue, tender point score (based on the number and severity of tender points), and functional symptoms. Of the selective serotonin reuptake inhibitors studied,

fluoxetine (Prozac) demonstrated benefit for pain, functional status, global well-being, sleep, morning stiffness, and tender points.<sup>26</sup>

There is little support for the use of monoamine oxidase inhibitors, bupropion (Wellbutrin), antiepileptics, or antipsychotics in the treatment of somatic symptom disorder. These medications have significant adverse effects and are best avoided for this use.<sup>25</sup>

Two randomized, double-blind, placebo-controlled trials reviewed the effectiveness and safety of St. John's wort for the treat-

**Table 3. The Somatic Symptom Scale-8**

During the past seven days, how much have you been bothered by the following symptoms?

Symptom	Not at all	A little bit	Somewhat	Quite a bit	Very much
Back pain	0	1	2	3	4
Chest pain or shortness of breath	0	1	2	3	4
Dizziness	0	1	2	3	4
Feeling tired or having low energy	0	1	2	3	4
Headaches	0	1	2	3	4
Pain in your arms, legs, or joints	0	1	2	3	4
Stomach or bowel problems	0	1	2	3	4
Trouble sleeping	0	1	2	3	4

Score: \_\_\_\_\_

Scoring: None to minimal (0 to 3); low (4 to 7); medium (8 to 11); high (12 to 15); very high (16 to 32).

Adapted with permission from Gierk B, Kohlmann S, Kroenke K, et al. The Somatic Symptom Scale-8 (SSS-8): a brief measure of somatic symptom burden. *JAMA Intern Med.* 2014;174(3):400.

**Table 4. CARE MD Approach to Somatic Symptom Disorder**

Component	Description
Consultation (psychiatry or cognitive behavior therapy)	Consult and collaborate with mental health professionals
Assessment	Evaluate for other medical and psychiatric diseases
Regular visits	Schedule short-interval follow-up to stop overuse of medical care (e.g., inappropriate emergency department visits, excessive calls) and avoid the need for symptoms to get an appointment; stress coping rather than cure
Empathy	Spend most of the time listening to the patient and acknowledge that what he or she is feeling is real
Medical-psychiatric interface	Emphasize the mind-body connection; avoid comments such as "there is nothing medically wrong with you"
Do no harm	Limit diagnostic testing and referrals to subspecialists; reassure the patient that serious medical diseases have been ruled out

Information from reference 17.

## SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	References
In addition to a comprehensive clinical interview and assessment for diagnostic criteria, the use of screening instruments, such as the Patient Health Questionnaire-15 or the Somatic Symptom Scale-8, should be considered in patients with suspected somatic symptom disorder.	C	14, 15
Cognitive behavior therapy and mindfulness-based therapy are effective for the treatment of somatic symptom disorder.	B	18-24
Amitriptyline, selective serotonin reuptake inhibitors, and St. John's wort are effective pharmacologic treatments for somatic symptom disorder.	B	25-27
Other antidepressants (monoamine oxidase inhibitors, bupropion [Wellbutrin], anticonvulsants, and antipsychotics) are ineffective for the treatment of somatic symptom disorder and should be avoided.	B	25

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.

**Table 5. Summary of Treatment Options for Somatic Symptom Disorder**

Modality	Evidence	Findings
Cognitive behavior therapy <sup>18-21</sup>	Multicenter randomized controlled trial, reviews of controlled clinical trials	Effective for treatment of somatic symptom disorder and medically unexplained symptoms "Health anxious" patients had sustained symptomatic benefit over two years, with no significant effect on total costs Reduced physical symptoms, psychological distress, and disability
Mindfulness-based therapy <sup>22-24</sup>	Meta-analysis of randomized controlled trials	May be effective in treating some aspects of somatic symptom disorder Significant and sustained improvements in clinical outcomes (overall symptom severity, depression, and anxiety) compared with control groups
Pharmacotherapy <sup>25</sup>	Systematic reviews of controlled trials	Amitriptyline shows benefit for one or more of the following outcomes: fatigue, functional symptoms, global improvement, morning stiffness, pain, sleep, and tender points Fluoxetine (Prozac) shows benefit for functional status, global well-being, morning stiffness, pain, sleep, and tender points Monoamine oxidase inhibitors, bupropion (Wellbutrin), antiepileptics, and antipsychotics showed no benefit and should not be used
St. John's wort <sup>26,27</sup>	Randomized, double-blind, placebo-controlled trials (lower-quality studies)	More effective than placebo for improvement in self-reported somatic symptoms; well-tolerated and safe

Information from references 18 through 27.

ment of somatic symptom disorder.<sup>26,27</sup> Both of these studies showed that St. John's wort was superior to placebo, and that it is well-tolerated and safe.

### Prognosis

Somatic symptom disorders are generally chronic, with waxing and waning symptoms. However, some studies have shown that patients can recover; the natural history of the disorders suggests that approximately 50% to 75% of patients with medically unexplained symptoms show improvement, whereas 10% to 30% deteriorate.<sup>28</sup> Better

prognostic indicators include having fewer physical symptoms and better functioning at baseline.<sup>28,29</sup> A strong, positive relationship between the physician and the patient is essential and should be coupled with frequent, supportive visits, while avoiding the temptation to medicate or test when these interventions are not clearly indicated.

**Data Sources:** Medline searches via Ovid and PubMed were completed using the key terms somatoform disorder, somatization, somatic, medically unexplained symptoms, and treatment. The search included reviews, meta-analyses and randomized controlled trials. Also searched were the Cochrane Database of Systematic Reviews, Essential Evidence Plus, UpToDate, and evidence-based guidelines

from the National Guideline Clearinghouse. Search dates: August 2014 through November 2014.

## The Authors

STUART L. KURLANSIK, PhD, is a behavioral medicine faculty member at Virtua Family Medicine Residency Program, Voorhees, N.J., and a clinical professor of psychology at Philadelphia (Pa.) College of Osteopathic Medicine.

MARIO S. MAFFEI, MD, is program director at Virtua Family Medicine Residency Program.

Address correspondence to Stuart L. Kurlansik, PhD, Virtua Health, 2225 Evesham Rd., Ste. 101, Voorhees, NJ 08043 (e-mail: skurlansik@virtua.org). Reprints are not available from the authors.

## REFERENCES

- Schaefer P, Ebell M, Wilkes M, Brown S. Somatization. <http://www.essentialvidenceplus.com/content/eee/634> [subscription required]. Accessed October 27, 2104.
- Rosendal M, Blankenstein AH, Morriss R, Fink P, Sharpe M, Burton C. Enhanced care by generalists for functional somatic symptoms and disorders in primary care. *Cochrane Database Syst Rev*. 2013;10:CD008142.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Washington, DC: American Psychiatric Association; 2013.
- Harris AM, Orav EJ, Bates DW, Barsky AJ. Somatization increases disability independent of comorbidity. *J Gen Intern Med*. 2009;24(2):155-161.
- Murray AM, Toussaint A, Althaus A, Löwe B. Barriers to the diagnosis of somatoform disorders in primary care: protocol for a systematic review of the current status. *Syst Rev*. 2013;2:99.
- Rask MT, Andersen RS, Bro F, Fink P, Rosendal M. Towards a clinically useful diagnosis for mild-to-moderate conditions of medically unexplained symptoms in general practice: a mixed methods study. *BMC Fam Pract*. 2014;15:118.
- Hatcher S, Arroll B. Assessment and management of medically unexplained symptoms. *BMJ*. 2008;336(7653):1124-1128.
- Croicu C, Chwastiak L, Katon W. Approach to the patient with multiple somatic symptoms. *Med Clin North Am*. 2014;98(5):1079-1095.
- Yates WR, Dunayevich E. Somatic symptom disorders. <http://emedicine.medscape.com/article/294908-overview>. Accessed August 5, 2014.
- Parker G, Gladstone G, Chee KT. Depression in the planet's largest ethnic group: the Chinese. *Am J Psychiatry*. 2001;158(6):857-864.
- Steinbrecher N, Koerber S, Frieser D, Hiller W. The prevalence of medically unexplained symptoms in primary care. *Psychosomatics*. 2011;52(3):263-271.
- Greenberg DB, Dimsdale J, Solomon D. Somatization: epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis. [http://www.uptodate.com/contents/somatization-epidemiology-pathogenesis-clinical-features-medical-evaluation-and-diagnosis?source=search\\_result&search=Somatization%3A+epidemiology%2C+pathogenesis%2C+clinical+feature](http://www.uptodate.com/contents/somatization-epidemiology-pathogenesis-clinical-features-medical-evaluation-and-diagnosis?source=search_result&search=Somatization%3A+epidemiology%2C+pathogenesis%2C+clinical+feature)
- Kocalevent RD, Hinz A, Brähler E. Standardization of a screening instrument (PHQ-15) for somatization syndromes in the general population. *BMC Psychiatry*. 2013;13:91.
- Gierk B, Kohlmann S, Kroenke K, et al. The Somatic Symptom Scale-8 (SSS-8): a brief measure of somatic symptom burden. *JAMA Intern Med*. 2014;174(3):399-407.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med*. 2002;64(2):258-266.
- Abbey SE, Wulsin L, Levenson JL. Somatization and somatoform disorders. In: Levenson JL, ed. *The American Psychiatric Publishing Textbook of Psychosomatic Medicine*. 1st ed. Washington, DC: American Psychiatric Publishing; 2005:261.
- McCarron RM. Somatization in the primary care setting. *Psychiatr Times*. 2006;23(6):32-34.
- Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial. *Lancet*. 2014;383(9913):219-225.
- Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. *Psychosom Med*. 2007;69(9):881-888.
- Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. *Psychosom Med*. 2007;69(9):889-900.
- Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. *Psychother Psychosom*. 2000;69(4):205-215.
- Lakhan SE, Schofield KL. Mindfulness-based therapies in the treatment of somatization disorders: a systematic review and meta-analysis. *PLoS One*. 2013;8(8):e71834.
- Segal ZV, Williams JM, Teasdale JD, Kabat-Zinn J. *Mindfulness-Based Cognitive Therapy for Depression*. 2nd ed. New York, NY: Guilford Press; 2013.
- Williams JM, Kuyken W. Mindfulness-based cognitive therapy: a promising new approach to preventing depressive relapse. *Br J Psychiatry*. 2012;200(5):359-360.
- O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. *J Fam Pract*. 1999;48(12):980-990.
- Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. *Psychosom Med*. 2004;66(4):538-547.
- Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial [published correction appears in *Psychopharmacology (Berl)*. 2003;167(3):333]. *Psychopharmacology (Berl)*. 2002;164(3):294-300.
- olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. *J Psychosom Res*. 2009;66(5):363-377.
- Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. *J Psychosom Res*. 2004;56(4):391-408.

**eTable A. The Patient Health Questionnaire-15**

**During the past four weeks, how much have you been bothered by the following symptoms?**

<i>Symptom</i>	<i>Not at all</i>	<i>A little</i>	<i>A lot</i>
Back pain	0	1	2
Chest pain	0	1	2
Constipation, loose bowels, or diarrhea	0	1	2
Dizziness	0	1	2
Fainting	0	1	2
Feeling tired or having low energy	0	1	2
Feeling your heart pound or race	0	1	2
Headaches	0	1	2
Menstrual cramps or other problems with your periods (women only)	0	1	2
Nausea, gas, or indigestion	0	1	2
Pain in your arms, legs, or joints	0	1	2
Pain or problems during sexual intercourse	0	1	2
Shortness of breath	0	1	2
Stomach pain	0	1	2
Trouble sleeping	0	1	2

**Score:** \_\_\_\_\_

*Scoring: No somatic symptom disorder (0 to 4), mild (5 to 9), moderate (10 to 14), severe (15 or higher).*

*Adapted with permission from Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):266.*